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Abstract: The aims of this study were to characterize the antifungal activity of amphotericin B against
Candida auris in a static in vitro system and to evaluate different dosing schedules and MIC scenarios
by means of semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modelling and simula-
tion. A two-compartment model consisting of a drug-susceptible and a drug-resistant subpopulation
successfully characterized the time-kill data and a modified Emax sigmoidal model best described the
effect of the drug. The model incorporated growth rate constants for both subpopulations, a death
rate constant and a transfer constant between both compartments. Additionally, the model included
a parameter to account for the delay in growth in the absence or presence of the drug. Amphotericin
B displayed a concentration-dependent fungicidal activity. The developed PK/PD model was able to
characterize properly the antifungal activity of amphotericin B against C. auris. Finally, simulation
analysis revealed that none of the simulated standard dosing scenarios of 0.6, 1 and 1.5 mg/kg/day
over a week treatment showed successful activity against C. auris infection. Simulations also pointed
out that an MIC of 1 mg/L would be linked to treatment failure for C. auris invasive infections and
therefore, the resistance rate to amphotericin B may be higher than previously reported.
Keywords: Candida auris; PK/PD model; amphotericin B; time-kill curves
1. Introduction
Candida auris is a multidrug-resistant fungal pathogen that has emerged globally as a
cause of different infections, such as severe cases of fungemia [1,2]. Candidemia due to this
pathogen is associated with a high rate of mortality, especially in immunocompromised
patients. Other risk factors for C. auris candidemia include previous exposure to antibiotics
and underlying diseases such as diabetes, cardiovascular diseases or COVID-19 [3,4].
Additionally, the virulence and pathogenic capacity of C. auris and the decreased
susceptibility to antifungal drugs is greatly worrying. Tentative epidemiological break-
points for available antifungal drugs have recently been published. Those reports highlight
that C. auris has high MIC values for polyenes, azoles, echinocandins and nucleoside ana-
logues [5,6]. However, MIC related susceptibility categorization of C. auris isolates should
be cautiously interpreted, since species-specific clinical breakpoints have not yet been
defined [7]. C. auris is resistant to fluconazole and both intrinsic and acquired resistance
has been reported [5,8]. Reduced susceptibility to the other azoles, including the newest
isavuconazole, has also been described [8]. Echinocandins are the first line treatment to
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treat C. auris infections [9], but resistance to these drugs or therapeutic failures can emerge
rapidly in C. auris [10].
Regarding amphotericin B, a wide range of MIC values has been reported, with resis-
tance rates ranging from 0 to 30% using 1 mg/L as cut-off [7,11–15]. Recently, amphotericin
B was described as the only in vitro fungicidal agent against C. auris, unlike echinocan-
dins [16]. These facts, alongside with the fact that amphotericin B is the first alternative
to echinocandins for C. auris infections [17,18], make it an interesting drug whose activity
against this pathogen needs to be studied in deep.
In the current worrying scenario of reduced effective treatments to deal with C. auris
infections, in vitro studies that use time–kill (T-K) curve experiments and pharmacoki-
netic/pharmacodynamic (PK/PD) models to simulate different dosing schedules and
activity profiles, offer an attractive tool to describe the observed antifungal activity and to
predict the efficacy of the studied drugs. There are few PK/PD models from in vitro kinetic
data developed for antifungal drugs and Candida: caspofungin and fluconazole against
Candida albicans [19]; voriconazole against Candida spp. [20]; and recently, anidulafungin
against Candida spp. [21]. However, despite the relevance of C. auris, PK/PD modelling of
antifungal drugs for this emergent species is still lacking.
The aim of this study was to develop a semi-mechanistic PK/PD model for ampho-
tericin B against C. auris that can (a) describe the in vitro T-K experiment of clinical isolates
of C. auris exposed to amphotericin B and (b) simulate the expected T-K curves for different
dosing regimens and MIC scenarios.
2. Materials and Methods
Six C. auris blood isolates from the outbreak in Hospital Universitario y Politécnico La
Fe (Valencia, Spain) were included in this study [22]. The MIC, defined as the minimum
concentration producing ≥90% growth reduction, was determined following EUCAST
guidelines [23]. The MIC of amphotericin B for the six isolates was 1 mg/L.
Amphotericin B was obtained from Sigma-Aldrich (Madrid, Spain) as a powder. Stock
solutions were prepared with DMSO as solvent and stored at −80 ◦C until use.
Static T-K curve experiments were carried out on flat-bottomed microtitre plates in
RPMI medium (Sigma-Aldrich), with a final volume of 200 µL per well at 37 ◦C for 48 h.
C. auris blood isolates were grown at 37 ◦C for 24 h prior to the start of the experiment
to obtain fungal cultures in early logarithmic phase growth. Cells were suspended in
sterile distilled water to achieve a starting inoculum size of 1–5 × 105 colony forming units
(CFU)/mL and added to the microtitre plate containing amphotericin B at concentrations
0.25, 0.5, 1, 2 and 4 times the MIC. Growth control was also measured by adding the
inoculum to wells containing RPMI medium without amphotericin B. Sample for viable
counts were taken at 0, 2, 4, 6, 8, 24 and 48 h, plated in triplicate onto Sabouraud dextrose
agar (SDA) and incubated for 24–48 h at 37 ◦C. Depending on drug concentration, samples
were either first diluted in PBS or plated directly. When it was expected a sterilizing activity,
the whole well was sampled onto an SDA plate. Experiments were performed in duplicate
for each isolate on different days. The lower limit of detection was 5 CFU/mL. However,
due to the well-known sterilizing activity of amphotericin B, all the samples that showed
no growth at all were considered to be 0 CFU/mL. Carryover effect was determined as
previously described [24].
The basis of the semi-mechanistic model included two fungal stages in the PD part of
the model, consisting of a drug-susceptible fungal subpopulation (S) and a drug-resistant
subpopulation (R) [25]. This two-subpopulation model accounted for the biphasic killing
behaviour observed in the individual isolate static T-K curves (individual plots not shown).
First-rate order constants that defined both populations were the natural growth rate
(kgrowth), natural death rate (kdeath) and the transfer constant from S into R (kSR). The
equation that described S subpopulation in the absence of drug was as follows:
dS/dt = kgrowthS × S × (1 − e−αt) − kdeath × S − kSR × S (1)
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where dS/dt is the change in the number of the S subpopulation as a function of time.
It was not possible to perform a simultaneous estimation of both kgrowthS and kdeath
in this experimental setting. Hence, in an initial fit, kgrowthS was estimated by fitting a
single-stage model [19] to the control data. Based on this estimation of kgrowth (0.118 h−1)
and on previous analysis, kdeath was then fixed to 0.01 h−1 for final parameter estimation
in the two-stage model. Parameter α accounted for the delay in growth observed due to
experimental settings.
A specific kgrowth was estimated for the R subpopulation (kgrowthR) to account for the
regrowth observed at certain concentrations from 24 to 48 h. The kdeath parameter was
negligible in the final equation describing R subpopulation, hence it was not considered in
the following equation:
dR/dt = kgrowthR × R + kSR × S (2)
As previously mentioned, kSR is the parameter that described the transfer of fungal





× (S + R)
Nmax
(3)
where S and R are the compartments with susceptible and resistant fungal populations,
respectively, and Nmax is the maximum total density of fungal population in the stationary
phase (in log CFU/mL).
The effect of amphotericin B on the fungal killing of the susceptible subpopulation





where Emax is the maximum achievable drug-induced fungal killing-rate constant, EC50
is the drug concentration necessary to achieve half the maximum effect, C is the drug
concentration and h is a Hill factor or sigmoidicity factor that modifies the steepness of the
slope and smoothens the curve.
The final model for the S and R subpopulations were described according to
Equations (2) and (5):
dS/dt = kgrowthS × S ×(1 − e−αt) − Drug effect × S − kdeath × S − kSR × S (5)
dR/dt = kgrowthR × R + kSR × S
All T-K data were transformed into log CFU/mL and simultaneously analysed in
NONMEM v7.4 with ADVAN13 subroutine and first-order conditional estimation method
(FOCE). Residual variability was estimated by using an additive model. As six clinical
isolates were analysed, inter-individual variability (IIV) was checked. Additionally, inter-
occasion variability (IOV) was also investigated to account for the variability that might
have arisen either from each experimental day or from microtitre plate batch preparation.
Model performance was assessed by precision of parameter estimates, changes in objective
function value (OFV) and evaluation of diagnostic plots. Final model selection was also as-
sisted by the performance of visual predictive checks (VPCs) and non-parametric bootstrap.
VPCs were performed and graphically represented with NONMEM and S-PLUS software,
stratified by concentration, with the experimental plots overlaid by the median and 95%
prediction interval of a simulated virtual population of 1000 individuals. Non-parametric
bootstrap was conducted by resampling 1000 datasets using Perl speaks NONMEM (PsN).
In vivo PK parameters for amphotericin B deoxycholate were extracted from a tricom-
partmental model previously described in the literature, V1 = 0.136 L/kg; V2 = 0.275 L/kg;
V3 = 1.4 L/kg; Cl = 0.013 L/h/kg; Q12 = 0.35 L/h/kg; and Q13 = 0.026 L/h/kg [26]. The ef-
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fect of treatments with standard clinical doses of 0.6, 1 and 1.5 mg/kg/day were simulated
for a virtual population of 1000 patients, considering free drug plasma concentrations for
a typical unbound fraction of 0.045 [27]. Additional simulations were performed to test








where d is a drug-independent constant and h is the Hill factor. The EC50 value for each
MIC scenario was then included in the PK/PD model and simulations were performed
similarly. All simulations were conducted with NONMEM and S-PLUS.
3. Results
3.1. Time-Kill Experiments
Graphical representation of mean T-K curves for all isolates and replicates is shown in
Figure 1. No antifungal carryover was observed. Amphotericin B showed concentration-
dependent fungicidal activity. Fungicidal effect (3 log reduction compared to initial in-
oculum) was rapidly achieved, at 2 and 4 h, for concentrations of 4 mg/L and 2 mg/L,
respectively. At concentrations of 1 mg/mL (equal to MIC), the effect was fungistatic
overall, with a biphasic killing kinetic trend that showed fungal regrowth by the end of the
experiment in some clinical isolates.
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3.2. Semi-Mechanistic PK/PD Modelling
The developed model was able to describe successfully the effect of amphotericin B
against the studied C. auris clinical isolates. This model could characterize the initial and
higher killing rate at the higher amphotericin B concentrations, 2 and 4 mg/L, as well as
the biphasic trend or regrowth observed in most experim ts with the concentration of
1 mg/L. A schematic illustration of the final model is shown in Scheme 1.
Pharmaceutics 2021, 13, 1767 5 of 12Pharmaceutics 2021, 13, x FOR PEER REVIEW 5 of 12  
 
 
Scheme 1. Schematic illustration of the final PK/PD model. The total fungal population consists of 
two different subpopulations (S + R), with a first-rate order constant (kSR) that describes the transfer 
of fungal cells from a susceptible state (S) to a resistant one (R). Amphotericin B (AMB) exerts its 
effect on the susceptible subpopulation. kgrowthS: growth-rate of susceptible subpopulation; kgrowthR: 
growth-rate of resistant subpopulation. kdeath: death-rate constant of the susceptible subpopulation. 
Final model parameters and the standard error of the estimates, alongside bootstrap 
estimations are presented in Table 1. Considering the standard errors and the bootstrap 
results, the parameters of the model were properly estimated. Candida related parameters 
were kgrowthS and kdeath for S subpopulation (0.111 h−1 and 0.01 h−1, respectively) and kgrowthR 
for R subpopulation (0.01 h−1). kdeath and kgrowthR were fixed whereas kgrowthS was allowed to 
be estimated. When the model incorporated different values of α (delay in growth) for the 
absence or presence of the drug, a better fit was achieved. A modified Emax sigmoidal 
model best described the effect of the drug; Emax was equal to 0.784 h−1 and EC50 was equal 
to 1.88 mg/L (1.88 times bigger than the MIC). Hill factor was fixed to enable a proper 
estimation of the PD parameters. Variability in the response was best captured by IOV on 
EC50 rather than IIV, where each occasion (four in total) was defined as each prepared 
batch of microtitre plates. Model appropriateness was supported by the VPCs depicted in 
Figure 2. 
Table 1. Parameter estimates (typical values and relative standard error –RSE– as CV %) and bootstrap estimates (mean 
and 95% CI) of the PK/PD model. 
Parameter Description 
Model Estimate and RSE 
(CV %) 
Bootstrap Estimate (Mean 
and 95% CI) 
kgrowthS (h−1) 
Fungal growth rate constant 
of the S subpopulation 0.111 (3%) 0.111 (0.101–0.116) 
kgrowthR (h−1) 
Fungal growth rate constant 
of the R subpopulation 0.01 (fixed) - 
kdeath (h−1) Fungal death rate constant  0.01 (fixed) - 
Emax (h−1) 
Maximum kill rate constant 
of amphotericin B  0.784 (12%) 0.795 (0.635–1.04) 
EC50 (mg/L) 
Concentration of amphoteri-
cin B at which 50% of the 
Emax is achieved 
1.88 (3%) 1.89 (1.78–2.05) 
h 
Hill factor that that modifies 
the steepness of the slope 
and smoothens the curve 
4 (fixed) - 
α (control) 
Delay in fungal growth in 
the absence of drug 0.748 (3%) 0.754 (0.664–0.882) 
α (drug) 
Delay in fungal growth in 
the presence of drug 0.231 (10%) 0.233 (0.193–0.274) 
Scheme 1. Schematic illustration of the final PK/PD model. The total fungal population consists of
two different subpopulations (S + R), with a first-rate order constant (kSR) that describes the transfer
of fungal cells from a susceptible state (S) to a resistant one (R). Amphotericin B (AMB) exerts its
ef ect on the susceptible subpopulation. kgrowthS: growth-rate of susceptible subpopulation; kgrowthR:
growth-rate of resistant subpopulation. kdeath: t t f t e s sceptible subpopulation.
Final odel para eters and the standard error of the estimates, alongside bootstrap
esti ations are presented in Table 1. Considering the standard errors and the bo tstrap
results, the parameters of the model were properly estimated. Candida related parameters
were kgr t S and kdeath for S subpopulation (0.111 h−1 and 0.01 h−1, respectively) and
kgrowthR for R subpopulation (0.01 −1). kdeat and kgrowthR were fixed whereas kgrowthS
was allowed to be estimate . When the model incorporat d different values of α (delay
in growth) for th absence or presence of the drug, a better fit was achieved. A modified
Emax sigmoi al model best described the effect of the drug; Emax was equal to 0.784 h−1
and EC50 was equal to 1.88 mg/L (1.88 times bigger than the MIC). Hill factor was fixed
to enable a proper estimation of the PD parameters. Variability in the response was best
captured by IOV on EC50 rather than IIV, where each occasion (four in total) was defined
as each prepared batch of microtitre plates. Model appropriateness was supported by the
VPCs depicted in Figure 2.
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Table 1. Parameter estimates (typical values and relative standard error –RSE– as CV %) and bootstrap estimates (mean and
95% CI) of the PK/PD model.
Parameter Description Model Estimate and RSE(CV %)
Bootstrap Estimate
(Mean and 95% CI)
kgrowthS (h−1)
Fungal growth rate constant
of the S subpopulation 0.111 (3%) 0.111 (0.101–0.116)
kgrowthR (h−1)
Fungal growth rate constant
of the R subpopulation 0.01 (fixed) -
kdeath (h−1) Fungal death rate constant 0.01 (fixed) -
Emax (h−1)
Maximum kill rate constant of
amphotericin B 0.784 (12%) 0.795 (0.635–1.04)
EC50 (mg/L)
Concentration of
amphotericin B at which 50%
of the Emax is achieved
1.88 (3%) 1.89 (1.78–2.05)
h
Hill factor that that modifies
the steepness of the slope and
smoothens the curve
4 (fixed) -
α (control) Delay in fungal growth in theabsence of drug 0.748 (3%) 0.754 (0.664–0.882)
α (drug) Delay in fungal growth in thepresence of drug 0.231 (10%) 0.233 (0.193–0.274)
Nmax (log CFU/mL) Maximum fungal density 7.66 (1%) 7.67 (7.47–7.87)
σ (log CFU/mL) Residual error 0.271 (14%) 0.270 (0.190–0.327)
π1 (%CV) Occasion 1 0 (fixed) -
π2 (%CV) Occasion 2 9.5 (35%) 9.22 (2.45–15.34)
π3 (%CV) Occasion 3 18.4 (24%) 18.76 (10.07–28.12)
π4 (%CV) Occasion 4 7.5 (37%) 7.13 (2.75–13.19)
3.3. Simulation of Standard Treatments Using Human PK Data
The simulated total and unbound concentrations of amphotericin B for typical intra-
venous dosing regimens of 0.6, 1 and 1.5 mg/kg/day and their expected activity on C. auris
after a one-week treatment are shown in Figure 3. None of the simulated standard dosing
scenarios showed successful activity against C. auris.
Additional simulations with MIC scenarios of 0.06, 0.125, 0.25 and 0.5 mg/L (with
EC50 of 0.12, 0.24, 0.47 and 0.94 mg/L, respectively) for a 1-week period are presented in
Figure 4.
Simulations with the lowest dose, 0.6 mg/kg/day, showed that a fungistatic activity
would be achieved at the 5th day of treatment for MIC values of amphotericin B of
0.06 mg/L. The next simulated dose, 1 mg/kg/day, resulted in fungicidal activity from the
second day onwards and fungistatic with the first administration. Finally, the highest dose
of 1.5 mg/kg/day led to a fungicidal endpoint immediately after the first administration.
Additionally, for an MIC of 0.125 mg/L a fungistatic effect would be achieved at the 3rd
day, and fungicidal at the 5th day at this highest dose level.
Pharmaceutics 2021, 13, 1767 7 of 12
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4. Discussion
C. auris is an emergent fungal pathogen with reduced susceptibility to first-line anti-
fungal agents. Amphotericin B is an antifungal drug with proven efficacy against invasive
candidiasis and a low resistance-rate despite more than six decades of use; a correct and
thorough knowledge about the activity of this drug against C. auris is necessary. To date,
most susceptibility studies on this pathogen have focused on the determination of the
MIC. The MIC is the standard PD parameter used as a marker of fungal susceptibility
and antimicrobial efficacy, yet it possesses some limitations. The antimicrobial activity
of drugs is a dynamic process, while MIC is a threshold value. Concentrations below or
above the MIC ar ignored and thus, a more precis and quantitative informa io about
the concentration-effect profile of the drug is often missing [29]. It is also noteworthy that
even for the same microbial species, same MIC values among different isolates can result
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in different killing kinetics [24]. Thus, studies that characterize the antimicrobial activity
beyond the measurement of MIC are needed. In vitro time–kill curves allow obtaining
more information about the effect of different drug concentrations on microbial population
over a time period. In combination with PK/PD M&S, these time–kill curve experiments
provide an interesting tool to predict and simulate untested scenarios that may help in
decision-making and design of further studies.
As determined for other species of Candida [30,31], in the present study amphotericin
B showed concentration-dependent activity against C. auris in T-K experiments. Fungicidal
activity was achieved at concentrations ≥2 mg/L and in less than 2 h. These results are in
agreement with the only published work based on T-K curve methodology against C. auris,
in which MIC values of amphotericin B were also 1 mg/L [16]. Additionally, this killing
kinetic pattern has also been described for other species of Candida that have been regarded
as resistant to amphotericin B treatment [31,32].
Few PK/PD models are available for antifungal agents [19–21]. To our knowledge,
the present study is the first work that used a semi-mechanistic approach to model the
antifungal activity of amphotericin B against C. auris. The static T-K experiments performed
showed fungal regrowth or a biphasic trend, and therefore, a semi-mechanistic model that
included two fungal subpopulations with different susceptibility to the drug best captured
this behaviour. This approach has been extensively applied to successfully model antibiotic
activity [25,33]. In the model of the present study, the emergence of resistance is triggered
by a high microbial count, with the susceptible population switching to a resistant one,
a process described by a first-order rate constant that also accounted for the self-limiting
growth rate, as it has been previously proposed by other authors [25,34]. The model best
fitted the data when a different growth rate constant for the resistant subpopulation was
defined (kgrowthR); this parameter was estimated to be 10 times lower than the growth rate
constant for the susceptible subpopulation (kgrowthS), which is in agreement with the ‘fitness
cost’ observed in some species of Candida when they develop resistance mechanisms [35].
Moreover, phenotypic switching during treatment with amphotericin B has been described
for Candida lusitaniae [36], a closely related species of C. auris. Nevertheless, the main
goal of model building was to accurately describe the antimicrobial activity and perform
simulations rather than to provide insight into resistance mechanisms, for which specific
microbiological and molecular procedures would be needed. On the other hand, the lack of
similar PK/PD models reports for C. auris or amphotericin B in the literature has precluded
comparisons.
A three-compartment model for amphotericin B deoxycholate [26] was implemented
for the simulation of plasma concentrations of the drug in human patients for dosing
regimens of 0.6, 1 and 1.5 mg/kg/day. The latter is more commonly used for invasive as-
pergillosis rather than for candidemia [37], but we considered this dosing schedule for sim-
ulation purposes too due to the low susceptibility profile of C. auris and the concentration-
dependent PD of amphotericin B shown in the present study, in concordance with other
in vitro and in vivo results [16,38]. Higher doses were not considered due to the toxicity
of the drug. Amphotericin B, as many antifungal agents, is highly bounded to plasma
proteins, around 95% at clinically achievable concentrations [27], and this feature was taken
into account in the PK/PD simulations.
With regard to the different pharmaceutical formulations available, liposomal am-
photericin B (L-AMB) is the current first choice due to its improved safety profile and
comparable efficacy to conventional amphotericin B deoxycholate. However, the cost can
be too high for healthcare systems in developing countries, which makes the conventional
formulation still relevant and listed as essential drug [39]. On the other hand, it is still
not clear which fraction of the total plasma concentration of L-AMB is active, as protein
binding is not applicable for this formulation [40], which makes the bridging between
in vitro experiments and in vivo simulations harder to perform. Therefore, the simulations
were carried out for the deoxycholate formulation. Nevertheless, studies in animal models
of invasive candidiasis and clinical trials have shown similar efficacy for both formula-
Pharmaceutics 2021, 13, 1767 9 of 12
tions [40]. This may reflect a comparable exposition of the fungal population to free drug
and therefore conclusions driven by PK/PD simulations may be applicable for L-AMB too.
In fact, EUCAST susceptibility breakpoints are based on adult standard dosages of both
formulations [41].
As previously mentioned, an approach solely based on the MIC of antimicrobials
provides limited information. Conversely, PD parameters derived from the analysis of
T-K curves, such as Emax and EC50, give more detailed information on the activity of the
drug. However, obtaining these data in the clinical setting is time-consuming, laborious
and usually not feasible. This drawback can be overcome by employing mathematical
relationship between the MIC and EC50, as it has been demonstrated in the present study,
since it is possible to link the results of the PK/PD modelling and simulation of T-K curves
with the MIC of the drug [28].
Simulations of standard dosages of amphotericin B deoxycholate pointed out that the
treatment would not be effective against the clinical isolates tested in this study. Addition-
ally, other possible treatment outcomes were tested by simulating different susceptibility
scenarios, with MICs below 1 mg/L. Standard treatments of 0.6 and 1 mg/kg/day would
only be effective against C. auris isolates for an MIC of 0.06 mg/L. However, a higher
dosage of 1.5 mg/kg/day would also be effective for an MIC up to 0.125 mg/L. Therefore,
contrary to expectations [7], susceptibility breakpoint of amphotericin B for C. auris might
be lower than 1 mg/L. Similar threshold values for amphotericin B have been reported for
other species of Candida and filamentous fungi, such as Aspergillus. In a murine model of
invasive candidiasis caused by Candida krusei, a daily dose of 1 mg/kg of amphotericin
B was effective in reducing the kidney fungal burden when the MIC of the drug was of
0.125 mg/L, but ineffective when MIC was of 0.5 mg/L [42]. In another murine model
study, doses of 1.5 mg/kg/day of amphotericin B resulted in a 15-day survival percentage
of >50% for Candida glabrata and <25% for Candida tropicalis, the MIC being 1 mg/L for
both species [43]. In an in vitro dynamic system that mimicked human PK of unbound
amphotericin B against Aspergillus, those species considered resistant to amphotericin B had
a probability of target attainment (PTA) of 0% when the MIC was 1 mg/L; for a PTA of 80%
an MIC of 0.25 mg/L was needed [44]. On the other hand, a work that analysed the effect
of antifungal drugs against C. auris infection in a murine model of invasive candidiasis
concluded that the MIC cut-off for amphotericin B was 1.5 mg/L [38]. However, variability
between strains was high and the 50% effective dose (ED50) was as high as 5 mg/kg/day, a
dose that can be lethal [45].
The results obtained in this study should be cautiously interpreted, as in vitro-in vivo
correlation studies for amphotericin B against C. auris are lacking. Even though T-K curve
methodology is a more complex technique that provides further information than MIC
determination, it is still an in vitro approximation to the much more complex in vivo reality.
Factors such as host immunity status and drug tissue distribution are overlooked, whereas
fungal burden may be overestimated, as growth rate is much faster in the rich environment
of the microbiological broth culture than in the human infection sites [46]. Nevertheless,
the developed model and simulation results may help in the design of future preclinical
and clinical studies, providing a useful tool for dosing regimen selection. It would also be
of interest to further confirm in a murine candidiasis model if the MIC of 1 mg/L is linked
to treatment failure.
5. Conclusions
In conclusion, the developed PK/PD model was able to properly characterize the
antifungal activity of amphotericin B against C. auris. The simulations highlighted that an
MIC of 1 mg/L would be linked to treatment failure and in consequence, the amphotericin
B resistance rate in this fungal species may be higher than previously reported [1]. These
results may be extrapolated to C. auris clinical isolates with similar EC50/MIC ratio. Never-
theless, further studies are needed to fully characterize the susceptibility profile of C. auris
and optimize antifungal therapy.
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